Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients

Inclusion Criteria: * Stage IV melanoma according to the 2001 AJCC criteria. Limited tumor burden; LDH \< 2x upper limit of normal * Histological proof of cutaneous melanoma * Melanoma expressing tyrosinase and/or gp100 (approximately 20% of cells or more determined by immunohistochemistry staining) * HLA Type A2 * WBC \> 3.0 \* 10E9/l, lymphocytes \> 0.8 \* 10E9/l, platelets \> 100 \* 10E9/l, serum creatinine \< 150 umol/l, serum bilirubin \< 25 umol/l, normal liver function * Expected adequacy of follow up * Written informed consent Exclusion Criteria: * autoimmune disorders, concomitant use of immunosuppressive drugs * serious concomitant disease, serious active infections, other malignancy in the past 5 years with the exception of curatively treated carcinoma in-situ of the cervix/squamous cell carcinoma of the skin * known allergy to shell fish (vaccine contains KLH) * pregnancy or lactation * clinical signs of CNS metastases, in patients with a clinical suspicion of CNS metastases, a CT scan of the brain should be performed to exclude this * prior chemotherapy, immunotherapy, or radiotherapy within three months before planned vaccination is allowed